Radioimmunotherapy with Yttrium-90 Ibritumomab tiuxetan for patients with relapsed cd20+ B-Cell non-Hodgkin’s Lymphoma

Current Treatment Options in Oncology

Volumn 3, Issue 4, 2002, Pages 275-282

  Alcindor, Thierry ^b   Witzig, Thomas E ^a  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

High Overall Response Rate; Ibritumomab Tiuxetan; Overall Response Rate; Peripheral Blood Stem Cell Transplant; Tositumomab

Indexed keywords

CD20 ANTIGEN; IBRITUMOMAB TIUXETAN; MONOCLONAL ANTIBODY; RITUXIMAB; YTTRIUM;

B CELL LYMPHOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; IMMUNOLOGY; METHODOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; HUMANS; LYMPHOMA, B-CELL; NEOPLASM RECURRENCE, LOCAL; RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 0036674723     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-002-0027-y     Document Type: Article

References (24)

1. Dinse GE, Umbach DM, Sasco AJ, Hoel DG, Davis DL: Unexplained increases in cancer incidence in the United States from 1975 to 1994: possible sentinel health indicators. Annu Rev Public Health 1999, 20:173–209. DOI: 10.1146/annurev.publhealth.20.1.173
2. Grillo-Lopez AJ, White CA, Varns C, et al.: Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma [review]. Semin Oncol 1999, 26:66–73.
3. Maloney DG, Liles TM, Czerwinski DK, et al.: Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDECC2B8) in patients with recurrent B-cell lymphoma. Blood 1994, 84:2457–2466.
4. McLaughlin P, Grillo-Lopez AJ, Link BK, et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825–2833.
5. Czuczman MS, Grillo-Lopez AJ, White CA, et al.: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999, 17:268–276.
6. Coiffier B, Lepage E, Briere J, et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002, 346:235–242. DOI: 10.1056/NEJMoa011795
7. DeNardo GL, DeNardo SJ, Goldstein DS, et al.: Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin’s lymphoma. J Clin Oncol 1998, 16:3246–3256.
8. DeNardo SJ, DeNardo GL, Kukis DL, et al.: 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma. J Nuclear Med 1999, 40:302–310.
9. Kaminski MS, Zasadny KR, Francis IR, et al.: Radioimmunotherapy of B-cell lymphoma with [131I] anti-B1 anti-CD20) antibody. N Engl J Med 1993, 329:459–465. DOI: 10.1056/NEJM199308123290703
10. Kaminski M, Estes J, Zasadny K, et al.: Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000, 96:1259–1266.
11. Vose JM, Wahl RL, Saleh M, et al.: Multicenter phase II study of iodine-131 tositumomab for chemotherapyrelapsed/ refractory low-grade and transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol 2000, 18:1316–1323.
12. Vose JM, Colcher D, Gobar L, et al.: Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin’s lymphoma. Leuk Lymphoma 2000, 38:91–101.
13. Liu SY, Eary JF, Petersdorf SH, et al.: Follow-up of relapsed B-cell lymphoma patients treated with iodine-131labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 1998, 16:3270- 3278.
14. Press O, Eary J, Liu S, et al.: A phase I/II trial of high dose iodine-131anti-B1 (anti-CD20) monoclonal antibody, etoposide, cyclophosphamide, and autologous stem cell transplantation for patients with relapsed B cell lymphomas. Proc Am Soc Clin Oncol 1998, 17:3a.
15. Press OW: Radiolabeled antibody therapy of B-cell lymphomas [review]. Semin Oncol 1999, 26:58–65.
16. Knox SJ, Goris ML, Trisler K, et al.: Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1996, 2:457–470.
17. Witzig TE, White CA, Wiseman GA, et al.: Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin’s lymphoma. J Clin Oncol 1999, 17:3793–3803.
18. Wiseman G, White C, Stabin M, et al.: Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma. Eur J Nucl Med 2000, 27:766–777. DOI: 10.1007/s002590000276
19. Witzig T, Gordon L, Wiseman G, et al.: Reduced dose Zevalin is safe and effective in patients with relapsed or refractory low grade follicular or CD20+ transformed B cell non-Hodgkin’s lymphoma and mild thrombocytopenia. Blood 2000, 96:728a.
20. Witzig Te, White Ca, Gordon L, et al.: Response to Zevalin is superior to response to rituximab regardless of age and extent of disease. Proc ASCO 2001, 20:279a.
21. Witzig T, White C, Flinn I, et al.: Zevalin radioimmunotherapy of rituximab-refractory follicular non-Hodgkin’s lymphoma. Blood 2000, 96:507a.
22. Witzig TE, Wiseman G: Clinical development of 90yttrium-conjugated murine anti-CD20 radioimmunoconjugates (90Y-ibritumomab tiuxetan, 90Y-Zevalin) for B-cell non-Hodgkin’s lymphomas. In Monoclonal Antibody Therapy of Hematologic Malignancies, edn 1. Edited by Cheson B. Abingdon, UK: Darwin Scientific Publishing Limited; 2001:203–214.
23. Press O, Eary J, Gooley T, et al.: A phase I/II trial of iodine-131tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000, 96:2934–2942.
24. Vose JM, Link BK, Grossbard ML, et al.: Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non- Hodgkin’s lymphoma. J Clin Oncol 2001, 19:389–397.